866-997-4948(US-Canada Toll Free)

Peritoneal Cancer - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Diseases & Conditions

No. of Pages : 759 Pages

Peritoneal Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H1 2017, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 12, 60, 36, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 4 and 1 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 6
Peritoneal Cancer - Overview 7
Peritoneal Cancer - Therapeutics Development 8
Peritoneal Cancer - Therapeutics Assessment 24
Peritoneal Cancer - Companies Involved in Therapeutics Development 40
Peritoneal Cancer - Drug Profiles 82
Peritoneal Cancer - Dormant Projects 734
Peritoneal Cancer - Discontinued Products 737
Peritoneal Cancer - Product Development Milestones 738
Appendix 745

List of Tables
Number of Products under Development for Peritoneal Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Peritoneal Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
Peritoneal Cancer - Pipeline by AbbVie Inc, H1 2017
Peritoneal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
Peritoneal Cancer - Pipeline by Aduro BioTech Inc, H1 2017
Peritoneal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
Peritoneal Cancer - Pipeline by Altor BioScience Corp, H1 2017
Peritoneal Cancer - Pipeline by Amgen Inc, H1 2017
Peritoneal Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Peritoneal Cancer - Pipeline by Astellas Pharma Inc, H1 2017
Peritoneal Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2017
Peritoneal Cancer - Pipeline by AstraZeneca Plc, H1 2017
Peritoneal Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017
Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Peritoneal Cancer - Pipeline by Bayer AG, H1 2017
Peritoneal Cancer - Pipeline by BeiGene Ltd, H1 2017
Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Peritoneal Cancer - Pipeline by Boston Biomedical Inc, H1 2017
Peritoneal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Peritoneal Cancer - Pipeline by Celgene Corp, H1 2017
Peritoneal Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
Peritoneal Cancer - Pipeline by Celsion Corp, H1 2017
Peritoneal Cancer - Pipeline by CerRx Inc, H1 2017
Peritoneal Cancer - Pipeline by Clovis Oncology Inc, H1 2017
Peritoneal Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Peritoneal Cancer - Pipeline by Eisai Co Ltd, H1 2017
Peritoneal Cancer - Pipeline by Eli Lilly and Company, H1 2017
Peritoneal Cancer - Pipeline by EpiThany Inc, H1 2017
Peritoneal Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
Peritoneal Cancer - Pipeline by Exelixis Inc, H1 2017
Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Peritoneal Cancer - Pipeline by Galena Biopharma Inc, H1 2017
Peritoneal Cancer - Pipeline by Gene Techno Science Co Ltd, H1 2017
Peritoneal Cancer - Pipeline by Genelux Corp, H1 2017
Peritoneal Cancer - Pipeline by Genentech Inc, H1 2017
Peritoneal Cancer - Pipeline by Genor BioPharma Co Ltd, H1 2017
Peritoneal Cancer - Pipeline by Glycotope GmbH, H1 2017
Peritoneal Cancer - Pipeline by Gradalis Inc, H1 2017
Peritoneal Cancer - Pipeline by Hemispherx Biopharma Inc, H1 2017
Peritoneal Cancer - Pipeline by ImmunoGen Inc, H1 2017
Peritoneal Cancer - Pipeline by Immunovaccine Inc, H1 2017
Peritoneal Cancer - Pipeline by Incyte Corp, H1 2017
Peritoneal Cancer - Pipeline by Innate Pharma SA, H1 2017
Peritoneal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Peritoneal Cancer - Pipeline by Johnson & Johnson, H1 2017
Peritoneal Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
Peritoneal Cancer - Pipeline by Lidds AB, H1 2017
Peritoneal Cancer - Pipeline by Mabion SA, H1 2017
Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
Peritoneal Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
Peritoneal Cancer - Pipeline by MedImmune LLC, H1 2017
Peritoneal Cancer - Pipeline by Medivir AB, H1 2017
Peritoneal Cancer - Pipeline by Merck & Co Inc, H1 2017
Peritoneal Cancer - Pipeline by Merck KGaA, H1 2017
Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Peritoneal Cancer - Pipeline by MolMed SpA, H1 2017
Peritoneal Cancer - Pipeline by Mycenax Biotech Inc, H1 2017
Peritoneal Cancer - Pipeline by NewLink Genetics Corp, H1 2017
Peritoneal Cancer - Pipeline by Novartis AG, H1 2017
Peritoneal Cancer - Pipeline by Novogen Ltd, H1 2017
Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2017
Peritoneal Cancer - Pipeline by OBI Pharma Inc, H1 2017
Peritoneal Cancer - Pipeline by Oncobiologics Inc, H1 2017
Peritoneal Cancer - Pipeline by Oncolix Inc, H1 2017
Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc, H1 2017
Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
Peritoneal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Peritoneal Cancer - Pipeline by Oxford BioMedica Plc, H1 2017
Peritoneal Cancer - Pipeline by Pfizer Inc, H1 2017
Peritoneal Cancer - Pipeline by Pharma Mar SA, H1 2017
Peritoneal Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Peritoneal Cancer - Pipeline by PsiOxus Therapeutics Ltd, H1 2017
Peritoneal Cancer - Pipeline by Richter Gedeon Nyrt, H1 2017
Peritoneal Cancer - Pipeline by Samyang Holdings Corp, H1 2017
Peritoneal Cancer - Pipeline by Sanofi, H1 2017
Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H1 2017
Peritoneal Cancer - Pipeline by Sotio AS, H1 2017
Peritoneal Cancer - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
Peritoneal Cancer - Pipeline by TapImmune Inc, H1 2017
Peritoneal Cancer - Pipeline by Tyrogenex Inc, H1 2017
Peritoneal Cancer - Pipeline by Vascular Biogenics Ltd, H1 2017
Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals Inc, H1 2017
Peritoneal Cancer - Pipeline by Verastem Inc, H1 2017
Peritoneal Cancer - Dormant Projects, H1 2017
Peritoneal Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Peritoneal Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
Peritoneal Cancer - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Peritoneal Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *